Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Usana Health Sciences (USNA) Cost of Revenue (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Cost of Revenue for 16 consecutive years, with $48.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Cost of Revenue rose 24.35% to $48.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $190.0 million, a 15.17% increase, with the full-year FY2024 number at $161.2 million, down 8.76% from a year prior.
  • Cost of Revenue was $48.8 million for Q3 2025 at Usana Health Sciences, down from $50.2 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $67.8 million in Q1 2022 to a low of $38.6 million in Q4 2024.
  • A 5-year average of $48.3 million and a median of $48.7 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: increased 25.17% in 2021, then plummeted 31.53% in 2022.
  • Usana Health Sciences' Cost of Revenue stood at $50.7 million in 2021, then decreased by 8.45% to $46.4 million in 2022, then decreased by 8.85% to $42.3 million in 2023, then dropped by 8.9% to $38.6 million in 2024, then rose by 26.62% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Cost of Revenue are $48.8 million (Q3 2025), $50.2 million (Q2 2025), and $52.4 million (Q1 2025).